A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

被引：0

作者：

Borque-Fernando, A. ^{[1
]}

Calleja-Hernandez, M. A. ^{[2
]}

Cozar-Olmo, J. M. ^{[3
]}

Gomez-Iturriaga, A. ^{[4
]}

Perez-Fentes, D. A. ^{[5
]}

Puente-Vazquez, J. ^{[6
]}

Rodrigo-Aliaga, M. ^{[7
]}

Unda, M. ^{[8
]}

Alvarez-Ossorio, J. L. ^{[9
]}

机构：

[1] Hosp Univ Miguel Servet, Serv Urol, IIS Aragon, Zaragoza, Spain

[2] Hosp Univ Virgen Macarena, Serv Farm, Seville, Spain

[3] Hosp Univ Virgen De Las Nieves, Serv Urol, Granada, Spain

[4] Hosp Univ Cruces, Serv Oncol Radioterap, Biocruces Bizkaia Hlth Res Inst, Baracaldo, Bizkaia, Spain

[5] Complejo Hosp Univ Santiago, Serv Urol, Santiago De Compostela, A Coruna, Spain

[6] Hosp Clin Univ San Carlos, Serv Oncol Med, Madrid, Spain

[7] Hosp Gen Univ Castellon, Serv Urol, Castellon de La Plana, Spain

[8] Hosp Univ Basurto, Serv Urol, Bilbao, Spain

[9] Hosp Univ Puerta Del Mar, Serv Urol, Cadiz, Spain

来源：

ACTAS UROLOGICAS ESPANOLAS | 2023年 / 47卷 / 02期

关键词：

Prostate cancer; Neoplasm metastasis; Patient safety; Clinical decision-making; Patient preference; Androgen antagonists; Docetaxel; ANDROGEN-DEPRIVATION THERAPY; SURVIVAL; GUIDELINE; DOCETAXEL; ENZALUTAMIDE; ABIRATERONE; PREVENTION; TOXICITY; AGENTS;

D O I：

10.1016/j.acuro.2022.12.004

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone thera-pies (abiraterone, apalutamide, or enzalutamide) improves overall survival and is currently the standard of care. However, the decision on the specific regimen to accompany ADT should be discussed with the patient, considering factors such as possible associated toxicities, duration of treatment, comorbidities, patient preferences, as there is no sufficient evidence to recom-mend one regimen over the other in most cases. This paper summarizes the evidence on the management of mHSPC and provides consensus recommendations on the optimal treatment in combination with ADT in mHSPC patients, with special attention to the patient's clinical profile.(c) 2023 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.

引用

页码：111 / 126

页数：16

共 71 条

[1]

AEMPS, FICH TECN AP

[2]

AEMPS, DOC FICH TECN

[3]

AEMPS, DAR FICH TECN

[4]

AEMPS, AB FICH TECN

[5]

AEMPS, ENZ FICH TECN

[6]

AEMPS, AP FICH TECN

[7]

AEMPS, FICH TECN DAR

[8]

AEMPS, FICH TECN ENZ

[9]

[Anonymous], 2020, ESP VID DIST ED

[10]

[Anonymous], ?About us"

← 1 2 3 4 5 6 7 8 →